Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer


Crinetics announces the appointment of Isabel Kalofonos as Chief Commercial Officer to lead global commercial strategy for the company’s first drug launch and its innovative pipeline of candidates.

Crinetics Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees.

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly


Crinetics announces the U.S. FDA accepted its New Drug Application for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults.

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences


Crinetics' management will participate in three upcoming investor conferences: the Evercore 7th Annual HealthConx Conference on December 3rd, the Citi Global Healthcare Conference on December 4th, and the Piper Sandler 36th Annual Healthcare Conference on December 5th.

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting


Crinetics to showcase pipeline advancements with neuroendocrine tumor candidates at the 2024 NANETS Annual Meeting.